Login
Companies $MEDP
$648.20 -$5.74 (0.88%) Live
Medpace Holdings, Inc. logo

Medpace Holdings, Inc.

investor.medpace.com

What Do They Do?

Provides outsourced clinical-trial services, including trial planning, monitoring and laboratory testing, to biotechnology, pharmaceutical and medical-device companies.

Who Are Their Customers?

Medpace sells directly to biotechnology, pharmaceutical and medical-device companies, including small and mid-sized biopharmaceutical firms and large pharmaceutical companies, through its business-development team.

Do Revenues Turn Into Profits?

Yes. It kept 18 cents of every revenue dollar as net income in FY2025 and turned 27 cents into free cash flow.

Operating income, FY2025
21% of revenue
▲ +20% vs FY2024 ($446.9M, 21%)
Net income, FY2025
18% of revenue
▲ +12% vs FY2024 ($404.4M, 19%)
Free cash flow, FY2025
27% of revenue
▲ +19% vs FY2024 ($572.3M, 27%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▲ +9%
vs $659.9M in Q3 FY2025
Net income
▲ +24%
vs $111.1M in Q3 FY2025
Metabolic share of revenue vs 29.2% in Q3 FY2025
Revenue over time
Oncology Metabolic Other Central Nervous System Cardiology AVAI Revenue net
$5B$2.5B$0

Who Do They Compete With?

Competes with IQVIA Holdings, ICON, PPD, and Fortrea

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support